UPDATE ON DEVELOPMENT OF STRATEGY FOR MIDDLE-INCOME COUNTRIES (MICs)

BOARD MEETING
Santiago Cornejo
4-5 December 2019, Delhi, India
Outline of the Board decision

Post-transition support to former Gavi-eligible countries to be institutionalised

Approach focusing on:
Political advocacy, technical assistance, innovation, access to pricing, and catalytic financial support to jumpstart vaccine introductions

<table>
<thead>
<tr>
<th>GNI per capita &lt;US$ 4,000</th>
<th>GNI per capita US$ 4,000 - US$ 6,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Many of these countries face similar challenges as former Gavi-eligible countries.</td>
<td></td>
</tr>
<tr>
<td>• To explore options to engage with these countries on the same set of modalities</td>
<td></td>
</tr>
<tr>
<td>• To also explore options to engage with these countries.</td>
<td></td>
</tr>
<tr>
<td>• However based on needs, the modalities of engagement may be different</td>
<td></td>
</tr>
</tbody>
</table>

**Resource allocation:** No more than 3.0% of Gavi 5.0 planned expenditure
Objectives and driving principles

Primary objectives

- Prevent Backsliding in former Gavi-eligible countries
- Sustainable introduction of key missing vaccines in former and never Gavi-eligible MICs

Secondary objectives

- Improve inter- and intra-country equity
- Maintain and improve access to sustainable pricing
- Open up access to new technologies and innovations
- Mobilise domestic resourcing

Driving principles

- Leverage the Alliance and partners’ expertise
- Reinforce and build on country and regional capacities
- Increase the efficiency of domestic resources
- A learning agenda

Board Meeting
4-5 December 2019
What causes backsliding and prevents new vaccine introductions? What can the Alliance do to address this?

Stakeholder consultations have identified interdependent drivers:

- **Low political will**
- **Programmatic bottlenecks**
  - Regulatory & procurement requirements
- **Unpredictable demand**
  - Unreliable forecasting & vaccine hesitancy
- **Unsustainable vaccine prices**
  - Driven by country risk profile perception

Tackling these through three mutually-reinforcing levers:

1. **Advocacy and political-will building**
2. **Targeted technical assistance**
3. **Innovative financing facility for pooled procurement**

Vaccine introductions
The country journey

Areas of Gavi support

- Health systems & immunisation strengthening
- Technical Country Assistance
- Co-financed vaccine support

Advocacy and political will building

Targeted Technical Assistance

Vaccine catalytic financing

Innovative financing facility for pooled procurement

Areas of Gavi support

- Advocacy and political will building
- Health systems & immunisation strengthening
- Technical Country Assistance
- Co-financed vaccine support

The country journey

- Initial self-financing
- Preparatory transition
- Accelerated transition
- Increasing domestic financing

- 100% % of Gavi vaccine cost
- $0.20 per dose
- Low-income country threshold
- Eligibility threshold
- End of Gavi financing
- End of price freeze for former Gavi-eligible
- UMICS <$4,000
- Fully self-financing
- Access to UMIC tiered price
- Former Gavi-eligible
- Fully self-financing
- Access to LMIC tiered price
- Access to price freeze for x years

DRAFT for discussion
THANK YOU

Reach every child
www.gavi.org